Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors
Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors
复制标题
DOI：
10.3109/14653249.2011.634402
复制
发表时间：
2012-02-01
期刊：
影响因子：
4.5
通讯作者：
Storek, Jan
中科院分区：
文献类型：
--
作者：
Hoegh-Petersen, Mette;Roa, Lina;Storek, Jan
背景的目标。识别自发解决巨细胞病毒（CMV）再激活的患者可以使这些患者免受抗病毒药物（如更昔洛韦）的毒性。CMV特异性T细胞在未接受更昔洛韦治疗的患者中清除CMV病毒血症的作用尚未得到评估。我们在巨细胞病毒血症患者中评估了这一点，这些患者的基因组拷贝数在5万到5万份/毫升之间，因为我们的起始更昔洛韦的阈值是5万份/毫升。方法。我们对39例CMV血清阳性的造血细胞移植（HCT）患者在首次CMV聚合酶链反应（PCR）阳性后4天内的CMV特异性T细胞进行了计数。CMV特异性T细胞被定义为在CMV裂解物或pp65重叠肽刺激下产生干扰素(IFN)- γ、肿瘤坏死因子(TNF)- α或白细胞介素(IL)-2的细胞，无论是单独的还是联合的。结果。捐助者(D)
Background aims. Identifying patients who spontaneously resolve cytomegalovirus (CMV) reactivation could spare these patients from the toxicity of antiviral drugs such as ganciclovir. The role of CMV-specific T cells in clearing CMV viremia in patients who do not receive ganciclovir has not been evaluated. We assessed this in patients with CMV viremia between 50 and 50 000 genome copies/mL, because our threshold for initiating ganciclovir is 50 000 copies/mL. Methods. We enumerated CMV-specific T cells in 39 CMV seropositive hematopoietic cell transplantation (HCT) recipients within 4 days of the first positive CMV polymerase chain reaction (PCR). CMV-specific T cells were defined as cells that upon stimulation with CMV lysate or pp65 overlapping peptides produced interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha or interleukin (IL)-2, alone or in combination. Results. Among Donor (D